Sponsored symposia

11:00 - 11:30

PHILIPS symposium

11:00 - 11:30 Direct to Angio Suite; the Next Paradigm Shift in Stroke Treatment - Raul G. NOGUEIRA, USA

13:30 - 14:15

STRYKER Symposium - Committed to Neurovascular Excellence: The Evolution of Stryker's Stent Innovation and Leadership

13:30 - 13:50 Neuroform Atlas: Changing Clinical Practice - Brian JANKOWITZ, USA
13:50 - 14:10 Early experience with the new Surpass Evolve Flow Diverter - Vincent COSTALAT, France & Timo KRINGS, Canada
14:10 - 14:15 Discussion

15:45 - 16:30

MICROVENTION Symposium - Brain Aneurysm Treatment: Latest Clinical Evidences
Moderator: I. SZIKORA, Hungary

15:45 - 16:05 WEB® Aneurysm Treatment: WEBCAST, WEBCAST II - 3 Years Follow Up - Laurent PIEROT, France
16:05 - 16:25 Hydrogel Endovascular Aneurysm Treatment Trial (HEAT) - Results - Guilherme DABUS, USA
16:25 - 16:30 Discussion

11:00 - 11:30

BALT symposium - Silk Vista baby, first experiences and future perspectives
Moderator: E. BOCCARDI, Italy

11:00 - 11:15 The Leipzig experience: reporting on the clinical outcomes and early results - Ulf QUASCHLING, Germany- Stefan SCHOB, Germany
11:15 - 11:30 Silk Vista baby experience and FIRST clinical study - Mario GALDAMEZ, Madrid

13:30 - 14:15

MEDTRONIC Symposium - Pipeline™ Embolization Device: 10 years of Leading Innovation
Moderator: M. MAWAD, Lebanon

13:30 - 13:50 Evolution of Technology reflected by Data - Istvan SZIKORA, Hungary
13:50 - 14:10 Repair of ruptured intracranial aneurysms using the Pipeline-Shield with Aspirin mono therapy - Nathan W. MANNING, Australia

15:45 - 16:15

PHENOX symposium

15:45 - 16:10 Recent evolution in Flow Diversion: p64, p48 MW and HPC - Laurent PIEROT, France
16:10 - 16:15 Discussion

17:15 - 17:45

CERENOVUS symposium - Treating Complex cases: my solution

11:00 - 11:30

CERENOVUS symposium - The Embotrap experience and First Pass efficacy in mechanical thrombectomy

11:00 – 11:20 Outcomes and Implications of FPE post ARISE II - Osama ZAIDAT, USA
11:20 – 11:30 In-Vitro comparison of Embotrap II efficacy - Vincent COSTALAT, France